BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 7822782)

  • 1. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain.
    Busch R; Vturina IY; Drexler J; Momburg F; Hämmerling GJ
    Eur J Immunol; 1995 Jan; 25(1):48-53. PubMed ID: 7843252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
    Long EO; LaVaute T; Pinet V; Jaraquemada D
    J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
    J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
    Lamb CA; Cresswell P
    J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II transport from lysosomal compartments to the cell surface is determined by stable peptide binding, but not by the cytosolic domains of the alpha- and beta-chains.
    Théry C; Brachet V; Regnault A; Rescigno M; Ricciardi-Castagnoli P; Bonnerot C; Amigorena S
    J Immunol; 1998 Sep; 161(5):2106-13. PubMed ID: 9725201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers.
    Hmama Z; Gabathuler R; Jefferies WA; de Jong G; Reiner NE
    J Immunol; 1998 Nov; 161(9):4882-93. PubMed ID: 9794422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
    Monji T; McCormack AL; Yates JR; Pious D
    J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DR alpha beta dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones.
    Demotz S
    Eur J Immunol; 1993 Sep; 23(9):2100-8. PubMed ID: 8370392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
    Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
    Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
    Adams S; Humphreys RE
    Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74).
    Koch N; Moldenhauer G; Hofmann WJ; Möller P
    J Immunol; 1991 Oct; 147(8):2643-51. PubMed ID: 1918985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens.
    Henne C; Schwenk F; Koch N; Möller P
    Immunology; 1995 Feb; 84(2):177-82. PubMed ID: 7750992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of the MHC class II molecules on B cells by peptide ligands.
    Agrawal B; Fraga E; Kane K; Singh B
    J Immunol; 1994 Feb; 152(3):965-75. PubMed ID: 8301149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
    Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
    Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.